JPH11514344A - インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 - Google Patents
インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法Info
- Publication number
- JPH11514344A JPH11514344A JP9510508A JP51050897A JPH11514344A JP H11514344 A JPH11514344 A JP H11514344A JP 9510508 A JP9510508 A JP 9510508A JP 51050897 A JP51050897 A JP 51050897A JP H11514344 A JPH11514344 A JP H11514344A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cell culture
- pkr
- activity
- defective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)少なくとも1つのインターフェロン刺激遺伝子の遺伝子産物の活性に欠 陥を有する細胞培養に供与ウィルスを感染させる工程、(b)効率的なウィルス成 長を提供するのに十分な条件下で感染細胞培養を培養する工程、及び(c)産生さ れたウィルスを採集する工程を有する動物ウィルスのウィルスワクチンの製造方 法。 2.細胞培養がPKR活性に欠陥を有するかまたは2−5A合成酵素活性に欠陥 を有するかまたは双方の活性に欠陥を有する請求項1記載の方法。 3.PKR欠陥細胞が、親細胞系にPKRアンチセンスポリヌクレオチドを核酸 感染させることによって得られる請求項2記載の方法。 4.PKR欠陥細胞が、親細胞系にPKR優性(−)変異体遺伝子を核酸感染さ せることによって得られる請求項2記載の方法。 5.優性(−)変異体が[Arg296〕PKRである請求項4記載の方法。 6.優性(−)変異体がネズミp65キナーゼの変異体である請求項4記載の方 法。 7.優性(−)変異体がウサギ網状赤血球から得られたPKRの変異体である請 求項4記載の方法。 8.優性(−)変異体がヒト末梢血単核球から得られたPKRの変異体である請 求項4記載の方法。 9.優性(−)変異体がイーストGCN2キナーゼの変異体である請求項4記載 の方法。 10.欠陥細胞培養が、PKRアンチセンスオリゴヌクレオチドの存在下で細胞系 を培養することによって得られる請求項2記載の方法。 11.欠陥細胞培養が、PKRタンパク質の抑制物質の存在下で細胞系を培養する ことによって得られる請求項2記載の方法。 12.抑制物質が2−アミノプリンである請求項11記載の方法。 13.欠陥細胞培養が、細胞系のインターフェロン応答性に必須のインターフェロ ンレセプターの抑制物質の存在下で細胞系を培養することによって得られる請 求項1記載の方法。 14.欠陥細胞培養がPKRおよび2−5A合成酵素の双方に欠陥を有する請求項 2記載の方法。 15.欠陥細胞培養がヒト細胞培養である請求項2記載の方法。 16.欠陥細胞培養が、MRC−5、WI−38、Chang肝、U937、Ve ro、MRC−9、IMR−90、IMR−91、Lederle130、MD CK、H9、CEM、およびCD4発現HUT78の群から選ばれる細胞系に由 来する請求項2記載の方法。 17.欠陥細胞培養がMRC−5またはWI−38またはVero細胞に由来する 請求項16記載の方法。 18.欠陥細胞培養が、U937細胞に由来する請求項2記載の方法。 19.供与ウィルスが弱毒ウィルスである請求項2記載の方法。 20.供与ウィルスが組換えウィルスである請求項2記載の方法。 21.供与ウィルスがヒトのウィルスである請求項2記載の方法。 22.供与ウィルスがヒトのインフルエンザウィルスである請求項21記載の方法。 23.供与ウィルスが非ヒトウィルスである請求項2記載の方法。 24.細胞培養がMxタンパク質活性に欠陥を有し、かつ供与ウィルスがインフル エンザウィルスまたは水疱性口内炎ウィルスである請求項1記載の方法。 25.欠陥細胞が変異インターフェロンレセプターを有し、かつインターフェロン に対して応答性をもたない請求項1記載の方法。 26.(a)インターフェロン特異的転写調節因子に欠陥を有する細胞培養に供与ウ ィルスを感染させる工程、(b)効率的なウィルス成長を提供するのに十分な条件 下で感染細胞培養を培養する工程、及び(c)産生されたウィルスを採集する工程 を有する動物ウィルスのためのウィルスワクチンを製造する方法。 27.転写調節因子がIRF1である請求項26記載の方法。 28.(a)インターフェロン発現を調節する因子の発現または活性に欠陥を有する 細胞培養に供与ウィルスを感染させる工程、(b)効率的なウィルス成長を提供す るのに十分な条件下で感染細胞培養を培養する工程、及び(c)産生されたウィル スを採集する工程を有する動物ウィルスのためのウィルスワクチンを製造する方 法。 29.因子がPKRである請求項28記載の方法。 30.因子がIRFIである請求項28記載の方法。 31.因子が2'−5'オリゴアデニレート合成酵素である請求項28記載の方法。 32.(a)インターフェロン仲介抗ウィルス応答に欠陥を有する細胞培養に供与ウ ィルスを感染させ、(b)効率的なウィルス成長を提供するのに十分な条件下で感 染細胞培養を培養する工程、及び(c)産生されたウィルスを採集する工程を有す る動物ウィルスのためのウィルスワクチンを製造する方法。 33.動物ウィルスに対抗する化合物の抗ウィルス活性を決定する方法であって、 (a)PKR活性に欠陥を有するか、または2−5A合成酵素活性に欠陥を有する 細胞培養に動物ウィルスを感染させる工程、(b)感染細胞培養を化合物で処理す る工程、(c)効率的なウィルス成長を提供するのに十分な条件下で感染細胞培養 を培養する工程、及び(d)産生されたウィルスの収量を決定する工程を有する、 上記方法。 34.動物ウィルスに対抗する化合物の抗ウィルス活性を決定する方法であって、 (a)感受性宿主細胞培養を動物ウィルスに感染させる工程、(b)感染細胞培養を化 合物で処理する工程、(c)処理細胞培養の細胞抽出物を調製する工程、(d)PKR 活性に欠陥を有するか、または2−5A合成酵素活性に欠陥を有するインジケー ター細胞培養を感染条件下で細胞抽出物に曝す工程、(e)最大のウィルス成長を 提供するのに十分な条件下で曝露細胞培養を培養する工程、及び(f)産生された ウィルスの収量を決定する工程を有する、上記方法。 35.動物ウィルスに対抗する化合物の抗ウィルス活性を決定する方法であって、 (a)動物ウィルスを化合物で処理する工程、(b)PKR活性に欠陥を有するか、ま たは2−5A合成酵素活性に欠陥を有するインジケーター細胞培養を感染条件下 で処理動物ウィルスに曝す工程、(c)最大のウィルス成長を提供するのに十分な 条件下で曝露細胞培養を培養する工程、及び(d)産生されたウィルスの収量を決 定する工程を有する、上記方法。 36.サンプル中のウィルスの存在を検出する方法であって、(a)PKR活性に欠 陥を有するか、または2−5A合成酵素活性に欠陥を有するインジケーター細胞 培養をウィルスを含むと思われるサンプルに感染条件下で曝す工程、(b)最大の ウィルス成長を提供するのに十分な条件下で曝露細胞培養を培養する工程、及び (c)ウィルスの存在について細胞培養を分析する工程を有する、上記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US262195P | 1995-08-22 | 1995-08-22 | |
US60/002,621 | 1995-08-22 | ||
PCT/US1996/013745 WO1997008292A1 (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11514344A true JPH11514344A (ja) | 1999-12-07 |
JP4267693B2 JP4267693B2 (ja) | 2009-05-27 |
Family
ID=21701659
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51045097A Expired - Fee Related JP3432519B2 (ja) | 1995-08-22 | 1996-08-22 | 細胞培養でインターフェロン産生を高める方法 |
JP51050897A Expired - Lifetime JP4267693B2 (ja) | 1995-08-22 | 1996-08-22 | インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51045097A Expired - Fee Related JP3432519B2 (ja) | 1995-08-22 | 1996-08-22 | 細胞培養でインターフェロン産生を高める方法 |
Country Status (10)
Country | Link |
---|---|
US (6) | US5840565A (ja) |
EP (2) | EP0846160B1 (ja) |
JP (2) | JP3432519B2 (ja) |
CN (1) | CN1161469C (ja) |
AT (1) | ATE289348T1 (ja) |
AU (2) | AU6857696A (ja) |
BR (1) | BR9610550A (ja) |
CA (2) | CA2229405C (ja) |
DE (1) | DE69634360T2 (ja) |
WO (2) | WO1997008324A1 (ja) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
US6855519B2 (en) * | 1995-08-22 | 2005-02-15 | The Regents Of The University Of California | Methods for enhancing the production of interferon in cell culture |
US6740519B1 (en) | 1997-11-03 | 2004-05-25 | Mount Sinai School Of Medicine | Immortalized, homozygous stat1-deficient mammalian cell lines and their uses |
US6573079B1 (en) | 1998-06-12 | 2003-06-03 | Mount Sinai School Of Medicine Of New York University | Methods and interferon deficient substrates for the propagation of viruses |
US6762038B1 (en) * | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
CA2376487A1 (en) * | 1999-06-15 | 2000-12-21 | Allan S. Lau | Methods for enhancing the production of cytokines in cell culture |
EP1067179A1 (en) * | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
DE60035515T2 (de) * | 1999-09-08 | 2008-04-17 | GeneTrol Biotherapeutics, Inc., Oakland | Hohe zytokinproduktion mit verbesserter zelllebensfähigkeit |
US20010031859A1 (en) * | 1999-09-08 | 2001-10-18 | Lau Allan S. | High level cytokine production with enhanced cell viability |
WO2001077394A1 (en) | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
IL136232A0 (en) * | 2000-05-18 | 2001-05-20 | Bar Ilan University Res Author | Measurements of enzymatic activity in a single, individual cell in population |
AU2001278139A1 (en) * | 2000-08-04 | 2002-02-18 | Chiron Corporation | Enhanced replication of hcv rna |
US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
AU2001290855A1 (en) | 2000-09-14 | 2002-03-26 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
JP2005500816A (ja) * | 2000-12-19 | 2005-01-13 | ジーントロール バイオセラピューティクス, インコーポレイテッド | サイトカイン産生を増加するための増大したpkr発現を有する細胞 |
DE10104094C1 (de) * | 2001-01-31 | 2002-07-25 | Angelika Vallbracht-Flehmig | Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung |
JP4192097B2 (ja) * | 2001-10-25 | 2008-12-03 | バル−イラン ユニバーシティ | 相互作用型透明個別細胞バイオチッププロセッサー |
IL154677A0 (en) * | 2003-02-27 | 2003-09-17 | Univ Bar Ilan | A method and apparatus for manipulating an individual cell |
US7888110B2 (en) | 2003-06-26 | 2011-02-15 | Seng Enterprises Ltd. | Pico liter well holding device and method of making the same |
US20060240548A1 (en) * | 2003-06-26 | 2006-10-26 | Mordechai Deutsch | Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof |
US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
US8597597B2 (en) | 2003-06-26 | 2013-12-03 | Seng Enterprises Ltd. | Picoliter well holding device and method of making the same |
WO2005008626A1 (en) * | 2003-07-11 | 2005-01-27 | University Of North Carolina At Chapel Hill | Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop |
US20050064524A1 (en) * | 2003-08-11 | 2005-03-24 | Mordechai Deutsch | Population of cells utilizable for substance detection and methods and devices using same |
US20070219149A1 (en) * | 2003-08-11 | 2007-09-20 | The Research Foundation For Microbial Diseases Of Osaka University | Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
NZ591879A (en) * | 2003-10-23 | 2012-11-30 | Kineta Two Llc | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
EP2267154A1 (en) * | 2003-10-23 | 2010-12-29 | Illumigen Biosciences, Inc. | Oligoadenylate synthetase |
GB2429207A (en) | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
BRPI0506610A (pt) * | 2004-02-03 | 2007-05-02 | Chemagis Ltd | montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico |
AU2005214090B2 (en) * | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
ES2694123T3 (es) | 2004-06-01 | 2018-12-18 | Icahn School Of Medicine At Mount Sinai | Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos |
US7403647B2 (en) * | 2004-09-13 | 2008-07-22 | Seng Enterprises Ltd. | Method for identifying an image of a well in an image of a well-bearing component |
EP1763665A1 (en) * | 2004-07-07 | 2007-03-21 | Seng Enterprises Limited | Method and device for identifying an image of a well in an image of a well-bearing component |
WO2006021959A2 (en) * | 2004-08-25 | 2006-03-02 | Seng Enterprises Ltd. | Method and device for isolating cells |
US20060051369A1 (en) * | 2004-08-27 | 2006-03-09 | Taylor Deborah R | ADAR1 antiviral pathway |
US20080107683A1 (en) * | 2004-11-30 | 2008-05-08 | David Hone | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
US8038964B2 (en) | 2005-01-25 | 2011-10-18 | Seng Enterprises Ltd. | Device for studying individual cells |
US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
CN101155915B (zh) * | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
UA95446C2 (ru) * | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
DE102005034043B4 (de) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch |
US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
US20070141555A1 (en) * | 2005-10-11 | 2007-06-21 | Mordechai Deutsch | Current damper for the study of cells |
WO2007052245A1 (en) | 2005-11-03 | 2007-05-10 | Seng Enterprises Ltd. | Method and device for studying floating, living cells |
US20070196333A1 (en) * | 2006-02-23 | 2007-08-23 | Fu-Yung Lin | Composition comprising mixtures of IFN-alpha subtypes |
US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
CN103965347B (zh) | 2007-05-02 | 2017-07-18 | Ambrx公司 | 经修饰干扰素β多肽和其用途 |
US9145540B1 (en) | 2007-11-15 | 2015-09-29 | Seng Enterprises Ltd. | Device for the study of living cells |
WO2009081409A2 (en) | 2007-12-26 | 2009-07-02 | Seng Enterprises Ltd. | Device for the study of living cells |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
EP2133358A1 (en) * | 2008-06-10 | 2009-12-16 | Universitätsklinikum Freiburg | Rift valley fever virus-like particles and their use for immunization and as test system |
EP2318044B1 (en) * | 2008-08-01 | 2015-12-02 | Gamma Vaccines Pty Limited | Influenza vaccines |
US9884105B2 (en) * | 2008-12-16 | 2018-02-06 | Ology Bioservices, Inc. | Production of viral vaccine |
JP2013523175A (ja) | 2010-04-14 | 2013-06-17 | イーエムディー・ミリポア・コーポレーション | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
WO2012100302A1 (en) | 2011-01-27 | 2012-08-02 | Gamma Vaccines Pty Limited | Combination vaccines |
AU2013270793A1 (en) * | 2012-06-04 | 2014-12-11 | Novartis Ag | Improved safety testing |
EP2954055B1 (en) * | 2013-02-05 | 2018-04-11 | University of Georgia Research Foundation, Inc. | Cell lines for virus production and methods of use |
EP3261664A1 (en) | 2015-02-26 | 2018-01-03 | Boehringer Ingelheim Vetmedica GmbH | Bivalent swine influenza virus vaccine |
WO2017070167A1 (en) * | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
KR102651055B1 (ko) | 2016-03-24 | 2024-03-26 | 삼성디스플레이 주식회사 | 광학 필름 및 디스플레이 장치 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
JPS5754586A (en) * | 1980-09-18 | 1982-04-01 | Ajinomoto Co Inc | Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it |
US4579821A (en) * | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
JPS58209993A (ja) * | 1982-05-31 | 1983-12-07 | Mochida Pharmaceut Co Ltd | インタ−フエロンの産生方法 |
HU189706B (en) * | 1982-06-21 | 1986-07-28 | The Wellcome Foundation Ltd,Gb | Improved process for the production of interferon |
US4485038A (en) * | 1982-10-19 | 1984-11-27 | Health Research (Roswell Park Division) | Method for the production and purification of human leukocyte interferon |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4745053A (en) * | 1983-07-08 | 1988-05-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo | Process for producing human interferon and method for assaying the interferon productivity of blood |
JPS6062997A (ja) * | 1983-09-17 | 1985-04-11 | Mochida Pharmaceut Co Ltd | インタ−フエロンの生産方法 |
US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
DK0414475T3 (da) * | 1989-08-25 | 1998-02-09 | Chiron Corp | Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier |
US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
JPH05260981A (ja) * | 1992-03-02 | 1993-10-12 | Massachusetts Inst Of Technol <Mit> | ヘムに調節される真核細胞開始因子2αキナーゼをコードするDNA |
FR2689520B1 (fr) * | 1992-04-03 | 1996-07-19 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques. |
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
-
1996
- 1996-08-21 US US08/700,198 patent/US5840565A/en not_active Expired - Lifetime
- 1996-08-22 JP JP51045097A patent/JP3432519B2/ja not_active Expired - Fee Related
- 1996-08-22 EP EP96929066A patent/EP0846160B1/en not_active Expired - Lifetime
- 1996-08-22 CN CNB961977515A patent/CN1161469C/zh not_active Expired - Fee Related
- 1996-08-22 EP EP96929017A patent/EP0846174A4/en not_active Withdrawn
- 1996-08-22 CA CA002229405A patent/CA2229405C/en not_active Expired - Fee Related
- 1996-08-22 CA CA2229163A patent/CA2229163C/en not_active Expired - Lifetime
- 1996-08-22 AU AU68576/96A patent/AU6857696A/en not_active Abandoned
- 1996-08-22 BR BR9610550A patent/BR9610550A/pt not_active Application Discontinuation
- 1996-08-22 AT AT96929066T patent/ATE289348T1/de active
- 1996-08-22 WO PCT/US1996/013627 patent/WO1997008324A1/en not_active Application Discontinuation
- 1996-08-22 WO PCT/US1996/013745 patent/WO1997008292A1/en active IP Right Grant
- 1996-08-22 DE DE69634360T patent/DE69634360T2/de not_active Expired - Lifetime
- 1996-08-22 AU AU68608/96A patent/AU707130B2/en not_active Expired
- 1996-08-22 JP JP51050897A patent/JP4267693B2/ja not_active Expired - Lifetime
-
1999
- 1999-11-19 US US09/444,224 patent/US6159712A/en not_active Expired - Fee Related
-
2000
- 2000-06-12 US US09/591,813 patent/US6489144B1/en not_active Expired - Fee Related
- 2000-12-13 US US09/737,126 patent/US6686190B2/en not_active Expired - Lifetime
- 2000-12-13 US US09/736,748 patent/US6673591B2/en not_active Expired - Fee Related
-
2003
- 2003-11-24 US US10/722,349 patent/US7132271B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1161469C (zh) | 2004-08-11 |
JP3432519B2 (ja) | 2003-08-04 |
CA2229405A1 (en) | 1997-03-06 |
AU707130B2 (en) | 1999-07-01 |
US6159712A (en) | 2000-12-12 |
CA2229163A1 (en) | 1997-03-06 |
DE69634360T2 (de) | 2005-12-29 |
EP0846174A4 (en) | 2003-02-05 |
EP0846160B1 (en) | 2005-02-16 |
DE69634360D1 (de) | 2005-03-24 |
US6489144B1 (en) | 2002-12-03 |
CA2229163C (en) | 2011-04-05 |
JP4267693B2 (ja) | 2009-05-27 |
BR9610550A (pt) | 1999-07-06 |
WO1997008292A1 (en) | 1997-03-06 |
US20010001290A1 (en) | 2001-05-17 |
CA2229405C (en) | 2004-03-02 |
JPH11511324A (ja) | 1999-10-05 |
US20010001709A1 (en) | 2001-05-24 |
WO1997008324A1 (en) | 1997-03-06 |
US5840565A (en) | 1998-11-24 |
US6686190B2 (en) | 2004-02-03 |
EP0846160A4 (en) | 2002-01-02 |
US6673591B2 (en) | 2004-01-06 |
CN1200148A (zh) | 1998-11-25 |
US7132271B2 (en) | 2006-11-07 |
AU6857696A (en) | 1997-03-19 |
EP0846160A1 (en) | 1998-06-10 |
EP0846174A1 (en) | 1998-06-10 |
ATE289348T1 (de) | 2005-03-15 |
US20040157310A1 (en) | 2004-08-12 |
MX9801423A (es) | 1998-05-31 |
AU6860896A (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4267693B2 (ja) | インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 | |
Cheng et al. | Chicken STING mediates activation of the IFN gene independently of the RIG-I gene | |
Komatsu et al. | Interferon-γ induced type I nitric oxide synthase activity inhibits viral replication in neurons | |
JP2941804B2 (ja) | 変性された生きている偽狂犬病ウイルスを含有する偽狂犬病ワクチン | |
Pavlovic et al. | Enhanced virus resistance of transgenic mice expressing the human MxA protein | |
Huang et al. | Identification of orange-spotted grouper (Epinephelus coioides) interferon regulatory factor 3 involved in antiviral immune response against fish RNA virus | |
Bonni et al. | Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus | |
Marcus et al. | Interferon action: inhibition of vesicular stomatitis virus RNA synthesis induced by virion-bound polymerase | |
Johnson et al. | Role for innate IFNs in determining respiratory syncytial virus immunopathology | |
Vitour et al. | Induction and control of the type I interferon pathway by Bluetongue virus | |
Anderson et al. | The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. | |
De Benedetti et al. | Loss of (2'-5') oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections. | |
Sandberg et al. | Expression of alpha/beta interferons (IFN-alpha/beta) and their relationship to IFN-alpha/beta-induced genes in lymphocytic choriomeningitis | |
Schultz-Cherry et al. | Induction of apoptosis by influenza virus | |
Bovolenta et al. | Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element | |
JP2000503213A (ja) | カポジ肉腫関連ウイルスのユニークな配列およびその使用 | |
CN107096015A (zh) | 一种新型抗病毒分子Kdm6a的抗病毒作用及其应用 | |
KR20240001198A (ko) | Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 | |
Azzam-Smoak et al. | Interferon regulatory factor-1, interferon-β, and reovirus-induced myocarditis | |
MXPA98001423A (en) | Methods to improve the production of viral vaccines in cellular cultivation through interruption suppression | |
Sherry | The role of interferon regulatory factors in the cardiac response to viral infection | |
JP2003325188A (ja) | サイトカイン遺伝子組換えカイコおよびそのタンパク質の製造方法 | |
Gariglio et al. | Host genotype controls the ability of the ISGF3 complex to activate transcription of IFN‐inducible genes | |
US20070036787A1 (en) | Insulin-induced gene as therapeutic target in diabetes | |
Hamaguchi et al. | Analysis of Nuclear Accumulation of Influenza Nucleoprotein Antigen in the Presence of p‐Fluorophenylalanine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070619 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090210 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090219 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130227 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130227 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140227 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |